10 September 2024
10 September 2024
Article doesn't exist
Summit shared data from the HARMONi-2 study at the World Conference on Lung Cancer (WCLC) conference in San Diego.
The biotech, currently in preclinical stages, aims to advance its lead candidate for melanoma and TNBC to clinical studies in 2026.
The company plans to start a pivotal Phase II/III trial for its Treg cell therapy after it induced clinical remission and insulin remission in type 1 diabetics.
Vir has gained sole global rights to three clinical-stage TCEs for treating various cancer types.
GlobalData conducted a survey of 280 physicians for their opinions on the therapy from April to August.
INT's tolerisation approach is designed to minimise patient burden by reducing the frequency of treatment.
The facility is set to complete its final qualification process, with plans to manufacture a range of RSV vaccines by 2025.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
